Baron Health Care Fund stated the following regarding AstraZeneca PLC (NASDAQ:AZN) in its Q4 2024 investor letter: "Poor performance from AstraZeneca PLC (NASDAQ:AZN) also factored into the ...

Q4 2024 Earnings Call Transcript April 1, 2025 Operator: Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year ...

Despite financial constraints, AIM ImmunoTech Inc (AIM) progresses with promising clinical trials and strategic leadership ...

Second, thanks to the progress of our collaboration with AstraZeneca. Up to year-end 2024, $47 million have been paid to Cellectis under the joint research and collaboration agreement of which $25 ...

Reports Q4 revenue $1.99M vs $33.22M last year. “2024 has been an important year for Cellectis (CLLS): we are now developing three programs in collaboration with AstraZeneca (AZN). So far ...

Cellectis demonstrated robust performance in Q4 2024, significantly outperforming market expectations. The company’s strategic initiatives, including its partnership with AstraZeneca ...